CASE STUDY
Syner-G Helps Biotech Firm Successfully Advance Life-Saving Drug Through Manufacturing Startup and Clinical Trials
About
The client is a clinical-stage biotechnology company focused on the phase III development of an anti-interleukin-6 monoclonal antibody therapeutic for the potential treatment of chronic active antibody-mediated rejection, the leading cause of long-term rejection in kidney transplant recipients.
Challenge
The client had successfully advanced their drug asset to the end of Phase II clinical studies, and while they had an internal CMC (Chemistry, Manufacturing and Controls) specialist, they felt they needed a more robust, experienced team to move the drug through Phase III for manufacturing.
Solution
The client chose to partner with Syner-G based on the company’s deep expertise in CMC and project management and its reputation in the industry. Syner-G helps its clients design and implement science and risk-based, phase-appropriate solutions to expeditiously advance drugs during development. Syner-G’s CMC 360 and Regulatory Affairs business units operate in an integrated fashion to ensure full compliance with scientific standards and regulatory requirements.
Results
The client was highly impressed with the Syner-G team, not just with their depth of CMC expertise but also their professionalism, honesty, and friendliness, which helped them immediately integrate into the client company’s culture. They also appreciated Syner-G’s ability to manage every detail seamlessly, which helped relieve a great deal of pressure from the client’s team. The client also appreciated Syner-G’s openness about technical and budget issues, which was instrumental in keeping the project moving forward and meeting their goals.
One of the most impressive aspects of Syner-G’s efforts was their tireless work to find the right global manufacturer for the client’s product, including inviting the client’s employees to accompany them on international trips to meet with potential manufacturing partners. It quickly became clear that the Syner-G team was highly respected in the industry. They knew what questions to ask and did “incredible due diligence.”
The client also appreciated the level of project management expertise Syner-G displayed in every aspect of the project. They were very hands-on, working closely with the third-party manufacturer to ensure smooth operations and to coordinate all details and deadlines of the project. This included regular on-site meetings with the manufacturer, which was critical to the partnership’s success.
“The Syner-G team was professional, transparent, honest, and had a very objective view of the project—in addition to just being good people.”
The client’s drug candidate is currently in multi-national clinical studies, which is a testament to the success of the Syner-G partnership.